Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hansoh Pharmaceutical Group Co's Revenue for the
six
months ended in Dec. 2025 was $1,078 Mil. Hansoh Pharmaceutical Group Co's average Accounts Receivable for the
six
months ended in Dec. 2025 was $406 Mil.
Hence, Hansoh Pharmaceutical Group Co's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.66.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Hansoh Pharmaceutical Group Co Receivables Turnover Related Terms
Hansoh Pharmaceutical Group Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Receivables Turnover Chart
HNSPF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a Receivables Turnover of 2.66 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hansoh Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #464 out of 948 companies in the Drug Manufacturers industry, placing it in the top 48.9%.
Is Hansoh Pharmaceutical Group Co's Receivables Turnover too high?
Hansoh Pharmaceutical Group Co's current Receivables Turnover is 2.66. The Drug Manufacturers industry median Receivables Turnover is 5.07. Hansoh Pharmaceutical Group Co's value of 2.66 is 47.5% below this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #464 out of 948 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #464 out of 948 companies for Receivables Turnover. This puts Hansoh Pharmaceutical Group Co in the upper half of its industry. The industry median Receivables Turnover is 5.07. Hansoh Pharmaceutical Group Co's value of 2.66 is 47.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Receivables Turnover of 2.66 is 47.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Receivables Turnover is 2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.13, compared to a current price of $3.83 — trading 22.2% above its estimated fair value. The current Receivables Turnover is 2.66 and 47.5% below the Drug Manufacturers industry median of 5.07. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Receivables Turnover is 2.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 22.2% above its estimated GF Value™ of $3.13.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for HNSPF:
Receivables Turnover: 2.66
GF Value™: $3.13 vs. price of $3.83 (22.2% above fair value)
Industry Position: 47.5% below the Drug Manufacturers median (#464 of 948)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score
Get the complete analysis for HNSPF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
